ImmunityBio Q4 2026 Earnings Preview
Source: SeekingAlpha
2026-03-02 17:38:28 ET
More on ImmunityBio
- ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
- ImmunityBio: The Story Surrounding Anktiva So Far
- ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade)
- Top 10 Healthcare Stocks of February
- ImmunityBio forms Irish unit, distribution deal to improve Anktiva access in Europe
Read the full article on Seeking Alpha
For further details see:
ImmunityBio Q4 2026 Earnings Preview
ImmunityBio Inc.
NASDAQ: IBRX
IBRX Trading
-0.29% G/L:
$8.875 Last:
12,794,005 Volume:
$8.78 Open:
IBRX Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
February 27, 2026 07:30:00 am
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
February 26, 2026 07:30:00 am
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 25, 2026 09:00:00 am
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
IBRX Stock Data
$6,497,322,803
300,611,373
0.32%
122
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
